TIGER'S TAKE: On our watch list/trading list. Potential is very high for what looks to be a 'blockbuster' drug. Down a bit today due to the market and a bit cautious analyst, saying good news is already priced in. We would buy dips/sell short puts. $AMRNAmarin shares already pricing in Vascepa label expansion, says CitiCiti analyst Joel Beatty agrees with Amarin that an FDA panel for the Vascepa label expansion is unlikely given that less than two months remain until the action date of September 28. However, approval of a cardiovascular risk reduction claim for Vascepa is already priced in to the stock, Beatty tells investors in a research note. As such, the analyst does not expect much stock movement around the PDUFA date. Upside would be if a very broad label is granted, such as no triglyceride level cutoff, says Beatty. The analyst believes that for Amarin shares to reach his unchanged price target of $23, Vascepa sales need to reach his 2020 sales projection of $769M, which is a 91% increase above the current annual run rate of $401M. This is realistic, however, given the direct-to-consumer advertising planned to begin in Q2 of 2020, as many primary care physicians "relatively unfamiliar" with Vascepa will begin to be repeatedly asked about it by patients, contends the analyst. He keeps a Buy rating on Amarin.Source: (thefly.com) $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page.